BioMark Diagnostics Inc. ("BioMark" or the "Company") (CSE:BUX) (FSE:20B), a leader in next-generation diagnostics using metabolites, announces its strategy to expand operations into the U.S. with headquarters in Maryland's world-class biotechnology center. "Expansion of operations into the U.S. market is a critical step in our growth plan," said Rashid Ahmed, BioMark's President and CEO. "This move will support our ability to build upon our leadership position in developing highly sensitive diagnostics that can detect cancer at its very early stages using our proprietary metabolite approach. We are making significant progress in strengthening the clinical validation for our metabolite approach and we are looking to build on the BioMark brand in the U.S. market."